End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,470 IDR | +1.03% | -4.55% | -8.70% |
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- With a 2024 P/E ratio at 22.22 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.70% | 4.11B | B+ | ||
+54.07% | 809B | C+ | ||
+38.95% | 621B | B | ||
-7.05% | 351B | C+ | ||
+15.44% | 319B | B- | ||
+5.72% | 289B | C+ | ||
+14.21% | 238B | B+ | ||
-0.45% | 221B | A+ | ||
+14.58% | 218B | B- | ||
+7.42% | 166B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KLBF Stock
- Ratings PT Kalbe Farma Tbk.